Syngeneic stem cell transplantation for HIV-related lymphoma.
The treatment of human immunodeficiency virus (HIV)-related lymphoma is beset by a number of therapeutic limitations. High-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) for relapsed disease is one option, but may be compromised by unacceptable treatment-related morbidity and mortality. We describe an HIV-positive male with relapsed immunoblastic non-Hodgkin's lymphoma (NHL) who successfully received salvage chemotherapy followed by a syngeneic PBSCT from his HIV-negative (hepatitis C positive) brother. At 15 months post-transplant he remains in complete remission with low-level HIV viral load, an improved CD4 lymphocyte count and absent anti-hepatitis C antibodies. We believe selected patients with relapsed HIV-related NHL should be considered for high-dose therapy.
Campbell
P
P
Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, N.S.W., Australia.
Iland
H
H
Gibson
J
J
Joshua
D
D
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011877:Radionuclide Imaging; D014750:Vincristine / Q000008:administration & dosage; D014916:Whole-Body Irradiation / Q000379:methods
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone